Overview

Study to Evaluate Pharmacokinetic and Safety of Albuvirtide Between Intravenous Drip and Intravenous Injection

Status:
Not yet recruiting

Trial end date:
2022-07-15

Target enrollment:

Participant gender:

Summary

This is a single-center,randomized,open, single-dose, parallel-design study, which will be only enrolled Chinese healthy volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

Frontier Biotechnologies Inc.